International Journal of Experimental Dental Science

Register      Login

VOLUME 4 , ISSUE 1 ( January-June, 2015 ) > List of Articles

RESEARCH ARTICLE

Platelet Growth Factor-enriched Plasma Therapy for Bisphosphonate-related Osteonecrosis of the Jaw: Biological Basis and Case Studies reviewed

Rosemary Dziak

Citation Information : Dziak R. Platelet Growth Factor-enriched Plasma Therapy for Bisphosphonate-related Osteonecrosis of the Jaw: Biological Basis and Case Studies reviewed. Int J Experiment Dent Sci 2015; 4 (1):0-0.

DOI: 10.5005/ijeds-4-1-iv

License: CC BY-SA 3.0

Published Online: 00-06-2015

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002;29(6 suppl 21):12-18.
  2. Bisphosphonates: clinical experience. Oncologist 2004;9(Suppl 4):14-22.
  3. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994;21(11): 2016-2020.
  4. Bisphosphonates and tumor burden. J Clin Oncol 2002;20(15):3191-3192.
  5. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis 1989;48(5):396-399.
  6. Therapeutic approaches to bone diseases. Science 2000;289(5484):1508-1514.
  7. Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates. Rheumatology Oxford 2014;53(10):1911-1913.
  8. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29(8):1548-1558.
  9. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. Hanover Park: IL; Quintessence Publishing Co Inc; 2007. p. 160.
  10. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7(6):508-514.
  11. American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011;142(11):1243-1251.
  12. A combination of platelet derived and insulin-like growth factors enhances periodontal regeneration. J Clin Periodontol 1989;16(8):545-548.
  13. Periodontal regeneration in class III furcation defects of beagle dogs using guided tissue regenerative therapy with platelet-derived growth factor. J Periodontol 1995;66(6):462-477.
  14. Platelet-derived growth factor mediated guided tissue regenerative therapy. J Periodontol 1995;66(6): 522-530.
  15. Comparative effects of plateletderived growth factor-BB and insulin-like growth factor-I, individually and in combination, on periodontal regeneration in Macaca fasciculars. J Periodont Res 1996;31(5):301-312.
  16. Effect of sustained gene delivery of platelet-derived growth factor or its antagonist (PDGF-1308) on tissue-engineered cementum. J Periodontol 2004;75(3):429-440.
  17. Recombinant human platelet-derived growth factor: biology and clinical applications. J Bone Joint Surg Am 2008;90(suppl 1):48-54.
  18. Effects of alendronate on human alveolar osteoblastic cells: interactions with platelet-derived growth factor. Int J Dent Oral Health 2015;1(12):1-6. Available at: http://dx.doi.org/10.16966/ijdoh.108.
  19. Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy. Int J Mol Med 2009;23(3):407-413.
  20. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8(5):1080-1084.
  21. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9(8): 2893-2897.
  22. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants 1999;14(4):529-535.
  23. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 2007;138(7):971-977.
  24. Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol 2012;48(5):469-474.
  25. A report on a 7-year follow-up of the surgical management with PRGF®-ENDORET® of oncologic patients affected by intravenous bisphosphonate related osteonecrosis of the jaw. Surgery 2013;1(2):1-4.
  26. Platelet rich plasma in the treatment of bisphosphonaterelated osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent 2014.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.